| Ytd | -31.64% | |
| 1y | -28.12% |
| Open | 8.18 | Prev Close | 8.19 | Low | 7.90 | High | 8.20 | Mkt Cap | 642.52M |
| Vol | 312.08K | Avg Vol | 1.31M | EPS | 1.89 | P/E | 4.33 | Forward P/E | 17.54 |
| Beta | 1.48 | Short Ratio | 5.12 | Inst. Own | 31.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 8.29 | 200-d Avg | 8.78 | 1yr Est | 16.25 |
CRMD News
US stock futures mixed, Dow futures up 0.2%. Frequency Electronics (FEIM) shares down 8.3% after rep
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers
US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock,
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reim
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds
The Federal Circuit's decision on Friday upheld the district court's findings that Nexus'
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today annou
CorMedix is rated a 'Strong Buy' below ~$8.35, with ~114% upside to a $17.5 fair value based on DCF
CorMedix NASDAQ: CRMD CEO Joe said the company is preparing for several potential commercial and reg
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger executio
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announ
CorMedix Therapeutics Inc. (NASDAQ:CRMD) raised its full-year 2026 revenue and adjusted EBITDA guida
CorMedix raises 2026 guidance after Q1 revenue surges on strong DefenCath demand and higher profitab
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix NASDAQ: CRMD reported sharply higher first-quarter 2026 revenue and profit, driven by conti
CorMedix (CRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Est
Cormedix (NASDAQ:CRMD) raises FY2026 sales outlook from $300.000 million-$320.000 million to $325.00
Cormedix (NASDAQ:CRMD) reported quarterly earnings of $0.43 per share which beat the analyst consens
‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million ; Adjusted EBITDA o
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnin
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announ
CorMedix Inc. (NASDAQ:CRMD) shares are up on Monday following the announcement of positive topline r
– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in
CorMedix is entering a post-TDAPA reset, with DefenCath revenue expected to decline materially and n
PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biophar
Here's a look at this week's earnings reports that are most likely to be watched by retail i
Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire'
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for it
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report